On Feb. 5, 2026, the Trump administration launched TrumpRx, a new online listing of discounted prescription medicines aimed at offering lower direct-to-consumer prices. The site, announced at a White House event, features dozens of drugs at steep reductions from list prices after the administration reached agreements with more than a dozen manufacturers, including Pfizer and Novo Nordisk.
TrumpRx does not fulfill prescriptions or sell drugs. Instead, it supplies a printable, gold-embossed coupon that customers can present at pharmacies. The site lists examples such as Wegovy injection pens priced at $199 for the first two months and $349 thereafter, compared with a list price of $1,349.02. A unit of Gonal‑F, used in some IVF treatments, appears at $252 on the site — roughly an 83% cut from the sticker price. Novo Nordisk has offered comparable Wegovy savings through its NovoCare Pharmacy program.
At the rollout, President Trump hailed TrumpRx as “one of the most transformative health care initiatives of all time,” and Joe Gebbia, an Airbnb co‑founder serving as the administration’s chief design officer, said additional drugs will be added over time.
How much the site will alter what most Americans pay is unclear. The vast majority of people obtain medicines through insurance, and the administration itself advises insured consumers to check their copays before using a cash coupon. Sean Sullivan, a health economist at the University of Washington, told CBS News last year that direct‑to‑patient cash discounts are largely a branding exercise because most patients have drug coverage and are unlikely to pay cash unless a product isn’t covered — a situation more common for some weight‑loss and erectile‑dysfunction treatments.
Still, steep cash discounts could matter for people without insurance, those with high deductibles, and patients whose drugs aren’t covered by their plans — including some users of weight‑loss medications and IVF treatments. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz encouraged consumers to check whether drugs on their lists are available at the discounted prices on TrumpRx.
The administration has also been pressing manufacturers to lower prices through other measures, including deals to make certain drugs available to Medicaid patients at most‑favored‑nation prices tied to costs in other high‑income countries. Lawmakers and presidents from both parties have long criticized how much more Americans typically pay for drugs than residents of other wealthy nations.
Drugmakers traditionally raise list prices at the start of each year. Data from drug‑pricing research nonprofit 46brooklyn showed manufacturers increased list prices for 947 brand‑name drugs in January 2026 and lowered prices for 20, with a median list‑price rise of about 4% so far in 2026. In some cases list prices have fallen sharply: Eliquis dropped 43% and Jardiance fell 44% after being among the first drugs selected for Medicare price negotiations under the Inflation Reduction Act.
The Consumer Price Index for prescription drugs, which reflects transaction costs rather than list prices, rose 2% between December 2024 and December 2025 and has declined by less than 1% since President Trump’s second‑term inauguration in January 2025.
Dr. Céline Gounder contributed to this report.